Loading…
← CockpitCompetitor Analysis › KIMS.NS Krishna Institute of Medical SciencesOpen in the cockpit ↗

Krishna Institute of Medical SciencesKIMS.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Hospital/Nursing Management

Hyderabad-based multi-specialty hospital chain expanding across south and east India.

Momentum neutral 59
Mkt cap
$3.41B
US dollars, full cap
Free float
59%
of shares outstanding
$/day
$3.24M
20-day average traded
Fwd P/E
81.9×
forward earnings
ROIC−WACC
-7.3 pp
WACC 12.2%
Hurdle
n/a
no reverse DCF
Next earnings
85 days
11 Feb 2027
Close · INR₹759.00
1D-1.2%
1W+4.5%
1M+11.9%
3M-5.8%
6M+2.4%
YTD+24.7%
1Y+10.4%
ATR %2.9%
Beta0.70
52w lowhigh11.5% off high

What Krishna Institute of Medical Sciences does

Hyderabad-based multi-specialty hospital chain expanding across south and east India.

Bills patients, insurers and state health schemes per treatment and occupied bed, so earnings follow beds, occupancy and revenue per bed, and a new hospital takes time to fill. Aarogyasri, a state insurance scheme in Telangana, is a significant payer. It has expanded outside its home base by building and buying hospitals.

Products and services

  • Multi-specialty tertiary care
  • Cardiac & oncology care
  • Maternity/obstetrics care

Customers

  • Domestic patients in south/east India

Where it sits in the supply chain

  • Healthcare services
  • Hospital/tertiary care
  • Regional multi-specialty hospital chain

What could go right

  • Regional healthcare demand growth
  • Bed capacity expansion

What could go wrong

  • Regional concentration risk
  • Capex/leverage for new hospitals

Moat: narrow (brand, installed base). Strong regional brand and bed capacity in Telangana/Andhra Pradesh with expansion into new states.

Headquarters: Hyderabad, India · Founded: 1973 · Employees: 18,491

Named competitors

Krishna Institute of Medical Sciences at a glance

Size Krishna Institute of Medical Sciences (KIMS.NS) is an India Health Care company (Hospital/Nursing Management) with a market value of $3.41B, the 267th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹759.00 on 18 Nov 2026.

Performance Over six months the shares gained 2.4%, against -0.9% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 35.1% over the last twelve months (peer median +8.8%); the operating margin is 11.0% (peer median 9.4%).

Valuation It trades at 81.9× forward earnings against a peer median of 37.3× (4th most expensive of 19).

Capital Return on invested capital runs 7.3 points below its cost of capital (12.2% WACC).

Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026KIMS.NS 100Peer median 99
Six months, rebased to 100: Krishna Institute of Medical Sciences against the median of its 20 peers (local-currency closes).

Krishna Institute of Medical Sciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹46.0B₹39.0B₹30.4B₹25.0B₹22.0B
Revenue growth—+29%+21%+14%—
Gross profit₹24.6B₹9.04B₹9.10B₹7.37B₹6.99B
EBITDA₹8.89B₹8.26B₹8.07B₹6.57B₹6.18B
Net income₹2.12B₹2.41B₹3.85B₹3.10B₹3.36B
Free cash flown/a-₹11.1B-₹5.42B-₹1.84B-₹1.51B
Capital expendituren/a₹14.3B₹10.1B₹6.47B₹5.75B
Total debt₹35.4B₹42.4B₹25.6B₹13.6B₹6.78B

Quarterly statements and history in the cockpit →

Krishna Institute of Medical Sciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%+20%SGRYNHCMEDANTANH600763BKDARDTEXE301267ASTERDMCHESIAPACS000516AEVSRHC301293SPIKIMS.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Krishna Institute of Medical Sciences is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%0×200×400×SGRYMEDANTANH600763BKDARDTEXEFORTISASTERDMSIAPACSAEVS301293KIMS.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Krishna Institute of Medical Sciences is the large dot.

Krishna Institute of Medical Sciences competitors and peer comparison

Head to head with its named competitors (KIMS.NS vs MEDANTA.NS vs NH.NS vs RAINBOW.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Krishna Institute of Medical Sciences KIMS.NS$3.41B+2%+35%11%81.9×n/a
Global Health MEDANTA.NS$4.13B+16%+26%17%50.4×n/a
Narayana Hrudayalaya NH.NS$4.13B0%+71%13%34.2×31.2%
Rainbow Childrens Medicare RAINBOW.NS$1.37B-7%+23%22%40.4×30.7%
Yatharth Hospital and Trauma Care Services YATHARTH.NS$1.13B+31%+50%16%49.4×n/a

How Krishna Institute of Medical Sciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Krishna Institute of Medical Sciences against its 20 peers (data as of 18 Nov 2026)
MeasureKIMS.NSPeer medianRank in peer set
1-month return+11.9%+1.7%4th highest of 21
6-month return+2.4%-0.9%9th highest of 21
Distance from 52-week high-11.5%-18.4%8th highest of 21
Revenue growth (TTM)+35.1%+8.8%4th highest of 21
Operating margin11.0%9.4%10th highest of 21
Forward P/E81.9×37.3×4th most expensive of 19
ROIC minus cost of capital-7.3 pp-2.5 pp4th lowest of 21
EV / EBITDA39.7×17.6×2nd most expensive of 15
Net debt / EBITDA3.5×3.8×9th least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Krishna Institute of Medical Sciences KIMS.NSIndia$3.41B+2%+35%11%81.9×n/an/a
Surgery Partners SGRYUnited States$3.53B+100%+2%13%77.2×15.6%+12.2%
National HealthCare NHCUnited States$3.16B+1%+6%0%n/a6.4%+9.7%
Global Health MEDANTA.NSIndia$4.13B+16%+26%17%50.4×n/an/a
Narayana Hrudayalaya NH.NSIndia$4.13B0%+71%13%34.2×31.2%+25.0%
Topchoice Medical 600763.SSChina$2.33B-12%+7%26%24.8×12.4%+6.9%
Brookdale Senior Living BKDUnited States$2.06B-36%-8%6%482.6×19.3%-1.4%
Ardent Health ARDTUnited States$2.03B+52%+2%5%11.9×-1.7%+8.7%
Extendicare EXE.TOCanada$1.91B-16%+36%9%19.3×10.8%+8.5%
Fortis Healthcare FORTIS.NSIndia$6.40B-17%+18%17%48.5×42.5%+17.9%
Huaxia Eye Hospital 301267.SZChina$1.78B-18%+2%15%23.5×2.1%+10.4%
Aster DM Quality Care ASTERDM.NSIndia$6.83B-2%+50%16%63.5×48.6%-11.6%
Chemed CHEUnited States$7.12B+24%+5%14%20.2×3.3%+4.0%
Sienna Senior Living SIA.TOCanada$1.58B-8%+15%10%40.9×18.9%+8.6%
PACS PACSUnited States$7.35B+25%+11%8%17.5×7.5%+29.7%
Xi'an International Medical Investment 000516.SZChina$1.46B-2%-1%-2%n/a12.7%+20.6%
Aevis Victoria AEVS.SWSwitzerland$1.43B+8%+15%-6%106.8×26.5%+10.2%
Ramsay Health Care RHC.AXAustralia$8.31B+41%+4%5%31.4×14.0%+8.3%
Rainbow Childrens Medicare RAINBOW.NSIndia$1.37B-7%+23%22%40.4×30.7%+21.2%
Sanbo Hospital Management 301293.SZChina$1.35B-29%+17%6%135.5×n/an/a
Spire Healthcare SPI.LUnited Kingdom$1.31B+11%+2%8%25.1×10.0%+11.4%

Questions

Who are Krishna Institute of Medical Sciences's main competitors?
Named competitors: Global Health (Medanta) (MEDANTA.NS), Narayana Hrudayalaya (NH.NS), Rainbow Children's Medicare (RAINBOW.NS), Yatharth Hospital (YATHARTH.NS). The cockpit's measured peer set (industry) also includes Surgery Partners (SGRY), National HealthCare (NHC), Global Health (MEDANTA.NS), Narayana Hrudayalaya (NH.NS), Topchoice Medical (600763.SS), Brookdale Senior Living (BKD).
Is Krishna Institute of Medical Sciences expensive compared with its peers?
On forward p/e it trades at 81.9× against a peer median of 37.3×, 4th most expensive of 19 in its peer set.
How has Krishna Institute of Medical Sciences stock performed?
Over six months to 18 Nov 2026 the shares returned +2.4% against -0.9% for the median peer; over one year +10.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.